ForSight Robotics vs ImmunoVec
Side-by-side comparison of AI visibility scores, market position, and capabilities
Ophthalmic robotics company raised $125M Series B in Jun 2025; first human cataract trials launching 2026; Oryom robot designed to reach any point within the human eye for cataract, retinal, and glaucoma procedures with precision exceeding human surgical capability.
About
ForSight Robotics is developing the Oryom — a surgical robot designed to reach any anatomical point within the human eye, enabling robotic cataract surgery, retinal procedures, and glaucoma interventions with precision exceeding human capability. The company raised $125 million in Series B financing in June 2025 and is launching its first human cataract trials in 2026, making it one of the most clinically advanced ophthalmic robotics companies globally. If the 2026 trial results are positive, an FDA submission pathway follows for the world's first robotic eye surgery system at clinical scale.
Received up to $40.7M ARPA-H award (Oct 2025). Polymeric nanoparticle platform to reprogram immune cells in vivo without viral vectors. Non-viral delivery for CAR-T-like therapies.
About
ImmunoVec is developing a non-viral polymeric nanoparticle delivery platform for in vivo immune cell engineering — programming a patient's immune cells directly inside their body without the expensive ex vivo manufacturing process that makes CAR-T therapies cost $500,000-$1,000,000 per treatment. The company received a selective ARPA-H (Advanced Research Projects Agency for Health) award of up to $40.7 million in October 2025 for development of its platform.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.